Pentapeptide-18 vs Semaglutide
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
Pentapeptide-18GLP-1 / Weight Loss Agonists
Semaglutide- Summary
- Pentapeptide-18 (Leuphasyl) is a synthetic pentapeptide that mimics the sequence of enkephalin, an endogenous neuropeptide. It acts on neuronal pain receptors in facial muscles to reduce muscle contraction intensity and depth of expression lines, functioning similarly to Argireline (Acetyl Hexapeptide-3) but via a different receptor mechanism.
- Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
- Half-Life
- Not applicable (topical)
- ~7 days
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.005–0.05% in formulation
- 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
- Frequency
- Twice daily
- Once weekly, subcutaneous
- Key Benefits
- Reduces depth of expression lines (forehead, crow's feet, glabellar)
- Inhibits acetylcholine release for muscle-relaxing effect
- Complementary mechanism to Argireline for enhanced anti-wrinkle activity
- Reversible and well-tolerated
- No risk of systemic paralysis at cosmetic concentrations
- Suitable for daily use in serums and creams
- Average 15–20% body weight reduction in clinical trials (STEP trials)
- Significant reduction in appetite and food cravings
- Improvement in blood sugar control and insulin sensitivity
- Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
- May reduce risk of kidney disease
- Improves metabolic markers (cholesterol, blood pressure)
- FDA-approved — extensively studied with robust safety data
- Weekly dosing convenience
- Side Effects
- Generally very well-tolerated topically
- Rare skin sensitivity or mild irritation
- Theoretical opioid receptor desensitization with very prolonged high-dose use (not documented cosmetically)
- Nausea (most common, especially during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- +4 more
- Stacks With
- —
- —